Slide 1: Corporate Presentation: Advancing Medicines for Solid Tumors
August 2023 Corporate Presentation Advancing Medicines for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances
Slide 3: Lead Program: CTIM-76, a Claudin 6 x CD3 Bispecific Antibody
Lead Program: CTIM-76, a Claudin 6 x CD3 Bispecific Antibody Opportunity • Claudin 6 (CLDN6) is a tumor-specific protein that is present at high surface density across many adult cancers1 • CLDN6 is expressed at very low levels or absent in normal adult tissue Challenge • CLDN6 antigen is conformati
Slide 4: Claudin-targeted Therapeutics are Gaining Momentum
Claudin-targeted Therapeutics are Gaining Momentum $263 million raised in 2023 for early-stage programs from TORL and Alentis Company Overview TORL Biotherapeutics (Private) Alentis Therapeutics (Private) Description Funding to advance TORL-1-23, a first-in-class, clinical- stage ADC targeting Claud
Slide 5: CTIM-76 Structure and Mechanism of Action
CTIM-76 Structure and Mechanism of Action Company Overview Context Therapeutics Inc. - August 20235 CTIM-76: Bispecific T Cell Engager Proposed Mechanism of Action • Humanized CLDN6 and CD3 binding domains • Half-life extended via Fc domain • Silenced Fc domain reduces FcγR binding • Ease of manufac
Slide 6: Bispecific Antibody T Cell Engagers in Solid Tumors
Bispecific Antibody T Cell Engagers (bsAb TCE) in Solid Tumors 2nd generation assets are addressing toxicity and dosing challenges associated with 1st generation products Company Overview Context Therapeutics Inc. - August 20236 1 Data as of August 1, 2023 Over 50 TCE in Clinical Development1Innovat
Slide 7: Claudin 6 (CLDN6) Target biology and therapeutic rationale
Claudin 6 (CLDN6) Target biology and therapeutic rationale Context Therapeutics Inc. - August 20237
Slide 8: CLDN6 is an Oncofetal Protein
CLDN6 is an Oncofetal Protein Oncofetal proteins are considered favorable candidates for immunotherapy • Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Increased expression known to occur in some tumor cells, including
Slide 9: CLDN6 Has the Potential to Reach a Large Patient Population
CLDN6 Has the Potential to Reach a Large Patient Population ~62,500 patients per year in the US only in Relapse/Refractory Setting CLDN6 Target Biology 9 Selected Cancer indications Incidence R/R Incidence CLDN6 Positive Patient Population Based on R/R Incidence Testicular 9,910 400 95%1 380 Ovarian
Slide 10: CLDN6 is Selectively Expressed on Cancer Cells
CLDN6 is Selectively Expressed on Cancer Cells CLDN6 Target Biology Context Therapeutics Inc. - August 202310 (a) adrenal gland, (b) fallopian tube, (c) kidney, (d) liver, (e) thyroid, (f) prostate, (g) esophagus, (h) stomach, (i) colon, (j) cerebrum, (k) cerebellum, (l) spinal cord. (m) thymus, (n)
Slide 11: High CLDN6 Associated with a Worsened Prognosis in Cancer Patients
High CLDN6 Associated with a Worsened Prognosis in Cancer Patients CLDN6 Target Biology Context Therapeutics Inc. - August 202311 Endometrial Cancer1 Overexpression of CLDN6 is associated with worse overall survival in endometrial cancer patients 1 Kojima, Cancers, 2020 2 Zhang, Front. Cell Dev. Bio
Slide 12: CLDN6 Has Limited Overlap with Competing Drug Targets in Solid Tumors
CLDN6 Has Limited Overlap with Competing Drug Targets in Solid Tumors CLDN6 Target Biology Context Therapeutics Inc. - August 202312 Bishop, AnalyzeR [Data Set] Accessed August 1, 2023 CLDN6 vs. TROP2 CLDN6 vs. NECTIN4 Respiratory Cancer Limited correlation with TROP2 and Nectin-4, no correlation wi
Slide 13: CTIM-76 Claudin x CD3 Development Candidate
CTIM-76 Claudin 6 x CD3 Development Candidate Context Therapeutics Inc. - August 202313
Slide 14: Developing a Highly Selective CLDN6 Antibody is Challenging
Developing a Highly Selective CLDN6 Antibody is Challenging CTIM-76 Program Context Therapeutics Inc. - August 202314 CLDN9 CLDN6 CLDN4 CLDN3 CLDN5 CLDN8 CLDN17 CLDN2 CLDN14 CLDN20 CLDN7 CLDN1 CLDN19 CLDN34 CLDN12 CLDN23 CLDN16 CLDN24 CLDN22 CLDN25 CLDN18 CLDN11 CLDN15 CLDN10 • CLDN6 antigen is conf
Slide 15: CTIM-76 Exhibits Excellent Selectivity and Potency
CTIM-76 Exhibits Excellent Selectivity and Potency CTIM-76 Program Context Therapeutics Inc. - August 202315 • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in HEK-293F cells (4:1 Target:GFP) CLDN6 Selectivit
Slide 16: CTIM-76 Induces Specific Lysis
CTIM-76 Induces Specific Lysis CTIM-76 showed potent and specific killing of even those cell lines with very low CLDN6 expression Context Therapeutics Inc. - August 202316 K562-CLDN6 OV90 HEK CLDN6 Expression High Medium Low CTIM-76 (EC50) 0.0004 nM 0.049 nM 2.79 nM OV90 Cell LineK562-CLDN6 Cell Lin
Slide 17: CTIM-76 Exhibits Limited Activation of Free Cytokines
CTIM-76 Program Context Therapeutics Inc. - August 202317 CTIM-76 Exhibits Limited Activation of Free Cytokines • Data supports potential to dose at levels that promote cancer cell killing but have manageable levels of free cytokine production, thereby potentially reducing the risk of cytokine relea
Slide 18: CTIM-76 Preclinical Data
CTIM-76 Preclinical Data CTIM-76 Program Context Therapeutics Inc. - August 202318 Preliminary efficacy, pharmacokinetics, and safety • CTIM-76 effectively engaged systemically administered human PBMC cells to promote significant tumor regression and complete responses in OV90 ovarian xenograft mode
Slide 19: Competitive Landscape
Competitive Landscape 19 Context Therapeutics Inc. - August 2023
Slide 20: CLDN6 Competitive Landscape
CLDN6 Competitive Landscape1 Context Therapeutics Inc. - August 202320 Preclinical Phase 1 Antibody Drug Conjugate (ADC) Bispecific Antibody Cell Therapy CLDN6-CAR-NK CAR-NK + IL7 BNT211 CAR-T + CARVac TJ-C64B 2+2 bsAb CLDN6x41BB TORL-1-23 CLDN6 + MMAE AMG794 BiTE CLDN6xCD3 BNT142 mRNA encoded BsAb
Slide 21: CLDN6 Programs Differentiated by Category, Selectivity, Potency, Manufacturability
Phase 1 Data Presented by BioNTech and TORL Biotherapeutics at ASCO 2023 CLDN6 programs differentiated by product category, selectivity, potency, and manufacturability CTIM-76 BNT211 TORL-1-23 Category T cell Engager CAR-T + CARVac ADC Mechanism of Action T cell activation and recruitment to CLDN6+
Slide 22: Phase Data Presented by BioNTech and TORL at ASCO 2023
Phase 1 Data Presented by BioNTech and TORL Biotherapeutics at ASCO 2023 BNT2111 TORL-1-232 Cutoff Date March 10, 2023 May 3, 2023 Patients (n) 19 (17 evaluable) 25 Median Prior Treatments, n (range) 4 (2-9) 5 (1-10) ORR, n (%) Overall: (7/17) 41% Dose Level 0 or 1: 11% (1/9) Dose Level 2: 75% (6/8)
Slide 23: Corporate
Corporate 23 Context Therapeutics Inc. - August 2023
Slide 24: Experienced Leadership Team
Corporate Experienced Leadership Team • Experienced team with deep oncology experience • Our CMO led the clinical development of multiple blockbuster drugs including Kisqali, Arimidex, and Afinitor • Our management team is supported by a Board with strong public company operating and governance expe
Slide 25: Corporate Investment Highlights
Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors Large Unmet Need Claudin 6 High-Value Target Anticipated Q1 2024 IND filing Near-Term Milestones Deep Domain Experience, Track Record of Success Strong Team Expected Cash Runway into late 2024 Financial Strength Context Therapeutics Inc. -
Slide 26: Advancing Medicines for Solid Tumors
Advancing Medicines for Solid Tumors © Context Therapeutics 2023